A combination of neratinib, fulvestrant and trastuzumab showed encouraging clinical activity in patients with hormone receptor (HR)-positive, HER2-negative, HER2-mutant metastatic breast cancer who had been treated with CDK4/6 inhibitors, according to results from the phase 2 SUMMIT trial.
SUMMIT is an open-label, multicenter, multinational, phase 2 basket study examining the efficacy and safety of neratinib (Nerlynx, Puma Biotechnology) as monotherapy or in combination with other